Correlation Between Acrivon Therapeutics, and Transcode Therapeutics

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Transcode Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Transcode Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Transcode Therapeutics, you can compare the effects of market volatilities on Acrivon Therapeutics, and Transcode Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Transcode Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Transcode Therapeutics.

Diversification Opportunities for Acrivon Therapeutics, and Transcode Therapeutics

0.64

Correlation Coefficient

Acrivon Therapeutics,  Transcode Therapeutics

Poor diversification

The 3 months correlation between Acrivon and Transcode is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Transcode Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Transcode Therapeutics and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Transcode Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Transcode Therapeutics has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Transcode Therapeutics go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Transcode Therapeutics

Given the investment horizon of 90 days Acrivon Therapeutics, is expected to generate 2.01 times less return on investment than Transcode Therapeutics. But when comparing it to its historical volatility, Acrivon Therapeutics, Common is 1.85 times less risky than Transcode Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Transcode Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  957.00  in Transcode Therapeutics on May 9, 2025 and sell it today you would earn a total of  154.00  from holding Transcode Therapeutics or generate 16.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Transcode Therapeutics

Acrivon Therapeutics,

Risk-Adjusted Performance

Mild

Compared to the overall equity markets, risk-adjusted returns on investments in Acrivon Therapeutics, Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Acrivon Therapeutics, showed solid returns over the last few months and may actually be approaching a breakup point.

Transcode Therapeutics

Risk-Adjusted Performance

Mild

Compared to the overall equity markets, risk-adjusted returns on investments in Transcode Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Transcode Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Acrivon Therapeutics, and Transcode Therapeutics

The main advantage of trading using opposite Acrivon Therapeutics, and Transcode Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Transcode Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Transcode Therapeutics will offset losses from the drop in Transcode Therapeutics' long position.

The idea behind Acrivon Therapeutics, Common and Transcode Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.